In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts

• Published in: Pediatric blood & cancer Vol. 70; no. 8; pp. e30398 - n/a
• Main Authors: Randall, Joanna, Evans, Kathryn, Watts, Ben, Smith, Christopher M., Hughes, Keira, Earley, Eric J., Erickson, Stephen W., Pachter, Jonathan A., Teicher, Beverly A., Smith, Malcolm A., Lock, Richard B.
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.08.2023
• Subjects: 1-Phosphatidylinositol 3-kinase; Acute lymphoblastic leukemia; Animals; CD45 antigen; Child; Chronic lymphocytic leukemia; Drug efficacy; duvelisib; Gene expression; Hematology; Heterografts; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Lymphatic leukemia; Lymphoma; Lymphoma, B-Cell - pathology; Malignancy; Mice; Mice, Inbred NOD; Morbidity; Oncology; patient‐derived xenografts; pediatric acute lymphoblastic leukemia; Pediatrics; Peripheral blood; Phosphatidylinositol 3-Kinases; PI3K; preclinical drug testing; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Xenografts; preclinical drug testing; PI3K; pediatric acute lymphoblastic leukemia; duvelisib; patient-derived xenografts

Background Acute lymphoblastic leukemia (ALL) remains one of the most common causes of cancer‐related mortality in children. Phosphoinositide 3‐kinases (PI3Ks) are a family of lipid kinases, and aberrations in the PI3K pathway are associated with several hematological malignancies, including ALL. Du...